Pharmacoeconomic evaluation of warfarin pharmacoge... [Expert Opin Pharmacother. 2011] - PubMed result

Expert Opin Pharmacother. 2011 Jan 14. [Epub ahead of print]
Pharmacoeconomic evaluation of warfarin pharmacogenomics.

You JH.

Centre for Pharmacoeconomics Research, School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong +852 2609 6830 ; +852 2603 5295 ; joyceyou@cuhk.edu.hk.

Abstract

Introduction: The merit of applying pharmacogenomics in the induction phase of warfarin therapy for personalized dosing is controversial and highly dependent on its cost-effectiveness. Areas covered: Published studies on pharmacoeconomics of warfarin pharmacogenomic application are reviewed. A literature search was done using Medline and Embase covering the period 2000 - 2010. Decision tree and Markov modeling were the most frequently used methods in the reviewed reports. Studies incorporating clinical efficacy data of genotype-guided dosing algorithm had shown that warfarin pharmacogenomics would improve quality-adjusted life-years (QALYs) gained. Nevertheless, it was unlikely to be cost-effective for general patients. Influential factors to improve the cost-effectiveness included low genotyping cost, high effectiveness in improving anticoagulation control/event rate, and applying warfarin pharmacogenomics to patients with high bleeding risk or at practice sites with suboptimal management of anticoagulation control. Expert opinion: Warfarin pharmacogenomics would improve QALYs and could possibly be cost-effective in selected patient groups or practice sites.

PMID: 21231897 [PubMed - as supplied by publisher]
Pharmacoeconomic evaluation of warfarin pharmacoge... [Expert Opin Pharmacother. 2011] - PubMed result